MDWD logo

MEDIWOUND LTD

MDWDNASDAQ
🏆 #3672 by market capEarnings Nov 19US Equity
$13.56▲ $1.01 (+8.05%)
🌅 Pre-market$13.20▼ 2.65%Regular close · extended-hours price shown
🔔
Track MDWD
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 8.1%
7d▲ 10.5%
14d▲ 11.4%
30d▼ 1.7%
ytd▼ 26.6%
1y▼ 25.0%
🏦Market Cap
$175M
Small Cap
📈Revenue Growth (YoY)
-16.1%
Declining
📊Gross Margin
15.5%
Thin
💵FCF Margin
-239.3%
Thin
⚖️P/S Ratio
14.8x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$12.61 – $13.61
52-Week Range
$11.80 – $19.70
Volume (shares)
126,554
Avg Volume (shares)
—
Shares Outstanding
12.9M
Next Earnings
2026-11-19

Fundamentals Snapshot

Annual Revenue
$17M
Last Q Revenue
$3M
P/E Ratio
-8.5
P/S Ratio
14.8x
EPS (TTM)
$-1.57
Dividend Yield
0.00%
Dilution (1yr)
+18.9%
MDWD logo

MEDIWOUND LTD

MDWD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$17M▼ −16.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
19.2%▲ +47.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$25M▲ +30.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$20M▲ +0.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
12.8M▲ +18.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$3M▼ −$6M YoY
StockOtter · stockotter.space

About MEDIWOUND LTD

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

Defense World·20d ago

Taysha Gene Therapies (NASDAQ:TSHA) versus MediWound (NASDAQ:MDWD) Head to Head Analysis

Taysha Gene Therapies (NASDAQ: TSHA - Get Free Report) and MediWound (NASDAQ: MDWD - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based

GlobeNewsWire·Sep 22

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid ®

GlobeNewsWire·Sep 14

Independent DSMB Recommends MediWound's EscharEx® Phase III VALUE Study Continue Without Modification

Independent DSMB Recommends MediWound's EscharEx ® Phase III VALUE Study Continue Without Modification DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment completion remain on

GlobeNewsWire·Sep 2

MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference

MediWound to Present at the H.C. Wainwright 28 th Annual Global Investment Conference YAVNE, Israel, September 2, 2026 -- MediWound Ltd.

Seeking Alpha·Aug 13

MediWound Ltd. (MDWD) Q2 2026 Earnings Call Transcript

MediWound Ltd. (MDWD) Q2 2026 Earnings Call Transcript

MarketBeat·Aug 13

MediWound Q2 Earnings Call Highlights

MediWound NASDAQ: MDWD reported second-quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier, as the company continued investing in its Phase III EscharEx chronic-wound program and expanded developm